Biointron - Antibody Discovery, Antibody Production, Stable cell line, Protein Expression, CRO

Recombinant antibody expression service — gene sequence to purified antibody in 2 weeks

Antibody discovery platform — VHH single-domain and fully human antibody screening

Affinity maturation optimization — CDR region site saturation mutagenesis

Recombinant Antibody Expression

Delivery in
2 weeks

From Gene Sequence to Purified Antibody

Learn More

Accelerating
Your Antibody Discovery

Learn More

AbDrop™: Discovery Fully Human Antibodies

Fully Human
Antibody Discovery

Rapid Generation of High-Quality, Fully Human Antibodies: Increased Diversity, Validated Candidates in Just 3 Months!

Learn More

Affinity
Maturation

No-bias Site Saturation Mutagenesis in CDR Region

Learn More

VHH Antibody
Discovery

Over 100 Projects Delivered Every Year

Learn More

Bispecific Antibody
Production

Any format BsAb can be customized

Learn More

About Us

0 ⁺

Years of Experience
0 ⁺

Employees
0 ⁺

Companies Served Globally
0 ⁺

Antibodies Delivered Annually

Why you should choose us

Pioneering Antibody Solutions

We specialize in antibody expression, discovery, and optimization with internationally recognized automated production standards - offering superior services at market- competitive rates with efficient turnaround times.
Unique Cell Line Commercialization

We possess exclusive re-licensing rights for the commercialization of the CHO-K1BN cell line licensed from ECACC.
Global Collaborative Excellence

Our partnerships with 3,000+ global biotech and pharmaceutical entities, coupled with our collaborative advancements in international clinical stages, solidify our esteemed position in the industry.
Trust and Exclusive Ownership

We commit to complete confidentiality - preserving the exclusive ownership rights of the antibodies we produce for our clients.

Engage with Biointron, your dependable partner for efficient, affordable, and top-tier custom antibody solutions.

About Biointron

Founded in 2012, and certified to ISO 9001:2015, Biointron is a CRO (Contract research organization) specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies.

Biointron is a leading high-throughput recombinant antibody/protein expression and discovery service provider. From gene sequence to purified antibodies, it just takes 2 weeks. Biointron has delivered tens of thousands of recombinant antibodies for 3,000+ biotech and pharma companies all over the world.

Client Voices: Biointron Success Stories

Learn from our partners and clients about the transformative impact of Biointron's expertise.

Check More Testimonials

"We evaluated the 6 proteins you produced for us and we were quite pleased by the results. our internal assessments of the molecules are very encouraging so we would like to potentially expand this further."

— AstraZeneca

"We have tested both batches of the antibodies you sent us. They're active and give comparable results with little batch to batch variation."

— AbbVie

"Excellent.The protein quality and activity was high and up to our standards, we appreciate the help and the work.The short timeline for the production is the main factor Biointron differs from other CROs."

— Moderna

"Great working with you, I've been highly impressed and recommending you to many in my network."

— Sanofi

"I just wanted to give you a quick heads-up regarding the expression we conducted at Biointron. Essentially, everything went well and was super fast, so we are all very much satisfied."

— Merck KGaA

"BioIntron was the best from the three: it was the only company that was able to express all the sequences and the yield for those proteins that the other two companies also could express was, generally, higher."

— ImmuVia, LLC

Our Latest News and Stories

Biointron Insights: Antibody Industry Outlook (2026 Insights, Trends & Analysis)

Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs have been approved by China, United States, Europe, and Australia.

Feb 01, 2026

Roundup of Antibody Biotech Deals in January 2026

January 2026 deal activity leaned heavily toward bispecific, trispecific, and ADC assets, particularly in oncology and immunology, alongside steady investment in AI-enabled target discovery and antibody engineering platforms. Several of the month’s largest transactions focused on late preclinical and early clinical programs, pointing to continued pharma interest in differentiated antibody modalities with well-defined mechanisms as the year gets underway.

Feb 06, 2026

HEK293 vs CHO Cells for Antibody Expression: Mechanistic Differences, Product Quality, and Strategic Implications

This article examines HEK293 and CHO across biological characteristics, productivity, glycosylation, product integrity, and application-specific strategy, integrating findings from recent comparative studies.

Jan 30, 2026

Learn More

Biointron Sets a New High in Cybersecurity Performance with 2026 CyberVadis “Mature” Rating

On February 22, 2026, Biointron successfully completed its latest third-party cybersecurity assessment conducted by CyberVadis, achieving an overall score of 923/1000 at the Mature security capability level, which is the highest level in the CyberVadis rating framework.

Feb 25, 2026

Biointron Awarded 2025 Scientist.com Supplier Performance Recognition Award

Biointron, a specialized antibody contract research organization (CRO), has been awarded the 2025 Scientist.com Supplier Performance Recognition Award for outstanding performance in delivering drug discovery research services throughScientist.com’sglobal R&D sourcing platform.Scient

Dec 17, 2025

New Publication Highlights Biointron’s AbDrop Platform for Plasma Cell-Based Antibody Discovery

The development of Biointron’s AbDrop, a scalable microfluidics-based platform for high-throughput identification and characterization of plasma cell-derived antibodies, was recently described in a study published in mAbs.

Dec 05, 2025

Learn More